Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older

INTRODUCTION: The incidence of herpes zoster (HZ) rises steeply after the age of 50 years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objective of this study was to estimate the cost-effectiveness of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Dermatol Ther (Heidelb)
Autors principals: Shiragami, Makoto, Mizukami, Akiko, Kaise, Toshihiko, Curran, Desmond, Van Oorschot, Desiree, Bracke, Benjamin, Watanabe, Daisuke
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6522608/
https://ncbi.nlm.nih.gov/pubmed/30929219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-019-0291-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars